Intrathecal Enzyme Replacement Therapy For Patients With Mucopolysaccharidosis Type I (Hurler Syndrome)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 09 Oct 2017
At a glance
- Drugs Laronidase (Primary)
- Indications Mucopolysaccharidosis I
- Focus Therapeutic Use
- 04 Oct 2017 Planned End Date changed from 1 Jun 2017 to 10 Nov 2017.
- 10 Jun 2017 Biomarkers information updated
- 22 Jan 2016 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017 as reported by ClinicalTrials.gov record.